155 related articles for article (PubMed ID: 33079606)
1. Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.
Catedral LI; Tan HN; Chua A; Benedict Sacdalan D; Sacdalan DL
JCO Glob Oncol; 2020 Oct; 6():1593-1608. PubMed ID: 33079606
[TBL] [Abstract][Full Text] [Related]
2. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.
Schink JC; Trosman JR; Weldon CB; Siziopikou KP; Tsongalis GJ; Rademaker AW; Patel JD; Benson AB; Perez EA; Gradishar WJ
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217578
[TBL] [Abstract][Full Text] [Related]
3. Biomarker Testing Trends in Patients With Metastatic Colorectal Cancer Who Live in Rural Areas and Urban Clusters in the US.
Lewis MA; Stansfield L; Kelton JM; Lieu CH
Oncologist; 2023 Nov; 28(11):e1118-e1122. PubMed ID: 37682042
[TBL] [Abstract][Full Text] [Related]
4. Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.
Iyer P; Deng M; Handorf EA; Nakhoda S; Dotan E
JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36149298
[TBL] [Abstract][Full Text] [Related]
5. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.
Mileham KF; Schenkel C; Bruinooge SS; Freeman-Daily J; Basu Roy U; Moore A; Smith RA; Garrett-Mayer E; Rosenthal L; Garon EB; Johnson BE; Osarogiagbon RU; Jalal S; Virani S; Weber Redman M; Silvestri GA
Cancer Med; 2022 Jan; 11(2):530-538. PubMed ID: 34921524
[TBL] [Abstract][Full Text] [Related]
6. Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal.
Tessier-Cloutier B; Cai E; Schaeffer DF
Diagn Pathol; 2019 Jun; 14(1):62. PubMed ID: 31221175
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
Gürün Kaya A; Çiledağ A; Erol S; Öz M; Doğan Mülazımoğlu D; Işık Ö; Özakıncı H; Çiftçi F; Şen E; Ceyhan K; Kaya A; Karnak D; Çelik G; İsmail S
Scott Med J; 2022 Feb; 67(1):18-27. PubMed ID: 35147461
[TBL] [Abstract][Full Text] [Related]
8. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
[TBL] [Abstract][Full Text] [Related]
9. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
Nadler E; Vasudevan A; Wang Y; Ogale S
Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
[TBL] [Abstract][Full Text] [Related]
10. Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists.
Waterhouse DM; Tseng WY; Espirito JL; Robert NJ
Clin Lung Cancer; 2021 Nov; 22(6):e901-e910. PubMed ID: 34187757
[TBL] [Abstract][Full Text] [Related]
11. Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey.
Prabhash K; Parikh PM; Rajappa SJ; Noronha V; Joshi A; Aggarwal S; Bondarde S; Patil S; Desai C; Dattatreya PS; Naik R; Anand S; Chacko RT; Biswas G; Sahoo TP; Dabkara D; Patil V; Chandrakant MV; Das PK; Vaid AK; Doval DC
South Asian J Cancer; 2018; 7(3):203-206. PubMed ID: 30112342
[TBL] [Abstract][Full Text] [Related]
12. Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities.
De Giglio A; Orlando V; Andrini E; Ricciuti B; Lamberti G; Chiari R
Tumori; 2023 Feb; 109(1):105-111. PubMed ID: 35120426
[TBL] [Abstract][Full Text] [Related]
13. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
14. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
15. Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011-2021.
Yan JT; Jin Y; Lo E; Chen Y; Hanlon Newell AE; Kong Y; Inge LJ
Oncol Ther; 2023 Sep; 11(3):343-360. PubMed ID: 37330972
[TBL] [Abstract][Full Text] [Related]
16. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
17. Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan.
Yatabe Y; Yoshiki Y; Matsumura K; Togo K; Kikkawa H; Iadeluca L; Li B; Nishio K
JTO Clin Res Rep; 2021 Mar; 2(3):100136. PubMed ID: 34589999
[TBL] [Abstract][Full Text] [Related]
18. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
19. Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Martín-López J; Rojo F; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; de Alda LR; García JF; Salas C
J Clin Pathol; 2023 May; 76(5):327-332. PubMed ID: 34903610
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
Vavala T; Malapelle U; Veggiani C; Ludovini V; Papotti M; Leone A; Graziano P; Minari R; Bono F; Sapino A; Manotti L; Troncone G; Pisapia P; Girlando S; Buffoni L; Righi L; Colantonio I; Bertetto O; Novello S
J Clin Pathol; 2022 Apr; 75(4):234-240. PubMed ID: 33509945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
